Evidence map›Paper›PMID 42334711›Full record

ArticleEJNMMI radiopharmacy and chemistry2026

Fully GMP-complient radiosynthesis of [

David Kryza, Pierre Le Fur, Jean Noël Badel, Clément Morgat, Fouzi Khayi, Anne-Laure Giraudet

Abstract read
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

David KryzaService de Médecine Nucléaire Lumen, Centre Léon Bérard, 69343, Lyon Cedex 08, France. david.kryza@lyon.unicancer.fr.
Pierre Le FurService de Médecine Nucléaire Lumen, Centre Léon Bérard, 69343, Lyon Cedex 08, France.
Jean Noël BadelService de Médecine Nucléaire Lumen, Centre Léon Bérard, 69343, Lyon Cedex 08, France.
Clément MorgatNuclear Medicine & Radiopharmacy Department, Bordeaux University Hospital, Bordeaux, France.
Fouzi KhayiService de Médecine Nucléaire Lumen, Centre Léon Bérard, 69343, Lyon Cedex 08, France.
Anne-Laure GiraudetService de Médecine Nucléaire Lumen, Centre Léon Bérard, 69343, Lyon Cedex 08, France.

Funding

Institut National Du Cancer PHRC-K 22-182
6 · The paper itself

Abstract

backgroundTerbium‑161 (

resultsEfficient radiolabeling was achieved under all the tested conditions, with RCPs consistently exceeding 97%. Optimal performance was observed when ascorbate buffer was used at 95 °C, yielding approximately 99% RCP at the end of synthesis. The addition of 40% (V/V) ethanol improved both the labeling efficiency and radiochemical stability, enabling high RCP even at lower temperatures. The final formulation demonstrated excellent stability, maintaining RCP ≥ 97.5% up to 48 h post-synthesis. All validation batches met predefined release criteria in accordance with Ph. Eur. Monograph radiopharmaceutical preparations. The total synthesis time was less than 30 min.

conclusionA robust, rapid, and fully automated GMP-compliant method for [

Indexed as

[161Tb]Tb-PSMA-1MiniAio synthesizerProstate cancerRadiolabeling optimizationTerbium-161

Identifiers

PMID42334711
PMCPMC13586091

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.